Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,585 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9% Sodium chloride Placebo Clear all
Completed Phase 2Phase 3 Interventional Results available

Trial of Rituximab for Graves' Ophthalmopathy

NCT00595335
View directory record Official record
Conditions
Thyroid-associated Ophthalmopathy
Interventions
Rituximab, Saline, Methylprednisolone
Drug
Lead sponsor
Rebecca Bahn
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 9, 2026, 5:41 AM EDT
Not listed Phase 2 Interventional

Trial of Steroids in Pediatric Acute Lung Injury/ARDS

NCT01274260
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), Acute Lung Injury (ALI)
Interventions
methylprednisolone, Normal Saline (0.9%)
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
1 Month to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 9, 2026, 5:41 AM EDT
Withdrawn Phase 4 Interventional

Randomized Controlled Trial Comparing Irrisept Versus Normal Saline for Wound Irrigation After Posterior Spine Surgery

NCT05408923
View directory record Official record
Conditions
Lumbar Spine Degeneration, Cervical Spine Degeneration
Interventions
saline 0.9%, (0.05% chlorhexidine gluconate (CHG) in sterile water)
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies

NCT00822523
View directory record Official record
Conditions
Muscle Strength, Botulinum Toxins, Type A
Interventions
Botulinum Toxin, Type A, Saline
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 54 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
2
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 1 Interventional

A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD Device

NCT02141191
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
inhaled hypertonic saline (7%)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 9, 2026, 5:41 AM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

NCT07059091
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Allergies
Interventions
Omalizumab (Xolair®), Sodium Chloride (NaCl) 0.9 %
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 9, 2026, 5:41 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

A Study of the Efficacy of Subcutaneous Phosphatidylcholine and Deoxycholate Injections for Localized Fat Removal

NCT00851747
View directory record Official record
Conditions
Obesity
Interventions
Phosphatidylcholine Deoxycholate, Saline
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
25 Years to 70 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 9, 2026, 5:41 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

NCT04504825
View directory record Official record
Conditions
AL Amyloidosis
Interventions
CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
26
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

NCT03135834
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
MenABCWY, Saline, rLP2086, MenACWY-CRM
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 25 Years
Enrollment
1,610 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Fountain Hills, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 2 Interventional

Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

NCT05495243
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
ARINA-1, Placebo
Drug
Lead sponsor
Renovion, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 9, 2026, 5:41 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

NCT04445285
View directory record Official record
Conditions
Covid19
Interventions
Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase), 0.9%sodium chloride
Drug
Lead sponsor
Jon Simmons
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intra-articular Pulsed Radiofrequency Neuromodulation Versus Intra-articular Steroids for Painful Knee Osteoarthritis

NCT04238598
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Pulse Radiofrequency, Standard of Care Intra- Articular Injection, Placebo Intra-Articular Injection
Procedure
Lead sponsor
Center For Interventional Pain and Spine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Exton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 9, 2026, 5:41 AM EDT
Active, not recruiting Phase 3 Interventional

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

NCT04498117
View directory record Official record
Conditions
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
Interventions
Oregovomab, Paclitaxel, Carboplatin, Placebo
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
81
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 70 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 1 Interventional

Muscle Anabolic Interventions to Accelerate Recovery From Hospitalization in Geriatric Patients

NCT02990533
View directory record Official record
Conditions
Aging
Interventions
Testosterone, Protein Supplement, Placebo Injection, Placebo supplement
Drug · Dietary Supplement · Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
65 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 9, 2026, 5:41 AM EDT
Not listed Phase 4 Interventional

Early Caffeine in Preterm Neonates

NCT03086473
View directory record Official record
Conditions
BPD - Bronchopulmonary Dysplasia, Apnea of Prematurity, Hemodynamic Instability, Intubation
Interventions
Caffeine Citrate, Placebo (Normal Saline)
Drug
Lead sponsor
Jennifer Shepherd
Other
Eligibility
Up to 1 Day
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

Study of Botulinum Toxin and Recovery of Hand Function After Stroke

NCT01422161
View directory record Official record
Conditions
Stroke With Hemiparesis
Interventions
Botulinum Toxin commonly known as BOTOX®, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial

NCT03389555
View directory record Official record
Conditions
Sepsis, Septic Shock, Metabolic Disturbance
Interventions
vitamin C, vitamin B1, hydrocortisone, Normal saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Phoenix, Arizona • Boston, Massachusetts • Cambridge, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 9, 2026, 5:41 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Platelet Rich Plasma Injections In Young And Old Human Subjects

NCT06451120
View directory record Official record
Conditions
Osteoarthritis, Articular Cartilage, Musculoskeletal Disorders
Interventions
Platelet-Rich Plasma (PRP) Injections, Centrifuge, Control saline injection
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

NCT04470427
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30,415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
100
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 9, 2026, 5:41 AM EDT
Terminated Phase 4 Interventional Results available

Clinical Trial of NAC in Asthma

NCT02605824
View directory record Official record
Conditions
Asthma
Interventions
n-acetylcystine, 0.9% saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 9, 2026, 5:41 AM EDT
Terminated Not applicable Interventional Results available

Intracolonic Vancomycin Therapy in Severe C. Diff Colitis

NCT01346059
View directory record Official record
Conditions
Colitis
Interventions
Vancomycin, Saline
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intravenous Lidocaine for Cystectomy Procedures

NCT02924480
View directory record Official record
Conditions
Invasive Bladder Cancer
Interventions
Cystectomy, Lidocaine, Saline
Procedure · Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults

NCT02142504
View directory record Official record
Conditions
Norovirus Prevention
Interventions
Norovirus Bivalent VLP Vaccine, Placebo (Saline)
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
454 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 9, 2026, 5:41 AM EDT